NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
12.82 ^CNY	+0.31%		+0.55%	-14.53%

Jan. 16	King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	MT
Jan. 11	NKFPharma Gets Certificate to Register Voriconazole for Injection	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	Jan. 16	MT
NKFPharma Gets Certificate to Register Voriconazole for Injection	Jan. 11	MT
Nanjing King-Friend’s Cancer Drug Get US FDA Nod	Dec. 28	MT
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	Dec. 22	MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	23-09-21	CI
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US	23-08-17	MT
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	23-07-26	MT
NKFPharma Unit Gets US FDA Nod for Cancer Drug	23-07-21	MT
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	23-06-27	MT
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide	23-05-10	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
NKFPharma Gets Certification for Lung Cancer Drug	23-04-11	MT
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	23-02-21	MT
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	22-12-15	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Chimigen Bio announced that it has received CNY 100 million in funding from Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd., Lapam Capital, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and other investors	22-09-21	CI
King-Friend Biochemical Wins FDA Nod to Market Cancer Treatment in US	22-09-08	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

Summary

Filters